<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03395548</url>
  </required_header>
  <id_info>
    <org_study_id>29-255 ex 16/17</org_study_id>
    <nct_id>NCT03395548</nct_id>
  </id_info>
  <brief_title>Stability of the Microbiome in IBD and IBS</brief_title>
  <official_title>Stability of the Intestinal Microbiome in Patients Suffering From Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS) Under the Influence of an Osmotic Laxans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators aim to investigate the changes of the intestinal microbiome&#xD;
      in three different cohorts (IBD, IBS, healthy) after applying the uniform disruptive factor&#xD;
      of osmotic diarrhea induced by macrogol. The investigators hypothesis is that ill people will&#xD;
      show more severe changes of the microbiome than healthy people and that these changes persist&#xD;
      longer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      I&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 25, 2017</start_date>
  <completion_date type="Actual">May 1, 2020</completion_date>
  <primary_completion_date type="Actual">May 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of the microbiome</measure>
    <time_frame>4 months</time_frame>
    <description>The investigators aim to asses the changes of the gut microbiome between the three Groups and before and after lavage (Alpha Diversity, Beta Diversity, Group Significance)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Microbiota</condition>
  <arm_group>
    <arm_group_label>Inflammatory bowel disease</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The aim is to recruit 20 persons suffering from Crohn's disease or ulcerative colitis with stable medication and stable control of the disease.&#xD;
As in each group the intervention will be the colon lavage with macrogol in combination with the colonoscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Irritable bowel syndrome</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The aim is to recruit 20 persons suffering from irritable bowel syndrome (IBS) fulfilling rome criteria.&#xD;
As in each group the intervention will be the colon lavage with macrogol in combination with the colonoscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The aim is to recruit 20 persons without known illnesses with a comparable age to the other two groups.&#xD;
As in each group the intervention will be the colon lavage with macrogol in combination with the colonoscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Macrogol</intervention_name>
    <description>Used drug: Macrogol (osmotic laxative)</description>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>Inflammatory bowel disease</arm_group_label>
    <arm_group_label>Irritable bowel syndrome</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with inflammatory bowel disease and irritable bowel syndrome and stable&#xD;
             therapy since three months&#xD;
&#xD;
          -  patients with the indication for colonoscopy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age under 18&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  new therapy planned&#xD;
&#xD;
          -  change of therapy within the last three months&#xD;
&#xD;
          -  acute exacerbation of the inflammatory bowel disease&#xD;
&#xD;
          -  colon pathologies of other origin: colocarcinoma, Illnesses with diarrhea&#xD;
             (f.e.microscopic colitis), short bowel syndrome, malabsorption, colectomy&#xD;
&#xD;
          -  intake of antibiotics in the last three months&#xD;
&#xD;
          -  intake of probiotics in the last month&#xD;
&#xD;
          -  intake of antibiotics or probiotics during the study&#xD;
&#xD;
          -  new proton pump inhibitor therapy&#xD;
&#xD;
          -  significant change of nutrition in the last three months&#xD;
&#xD;
          -  holidays outside europe in the last month&#xD;
&#xD;
          -  gastroenteritis in the last three months&#xD;
&#xD;
          -  intake of laxatives&#xD;
&#xD;
          -  nonsteroidal antiinflammatory drugs should be avoided and documented&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Blesl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universit√§tsklinikum Graz</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>8010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>January 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2018</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

